K S Slobod

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi Molecular evidence of ocular Epstein-Barr virus infection
    K S Slobod
    Departments of Infectious Diseases, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee, Memphis, Tennessee, TN, USA
    Clin Infect Dis 31:184-8. 2000
  2. ncbi HIV vaccines: brief review and discussion of future directions
    Karen S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, MS 320 332 N Lauderdale, Memphis, TN 38105, USA
    Expert Rev Vaccines 4:305-13. 2005
  3. ncbi Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults
    Karen S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Vaccine 22:3182-6. 2004
  4. ncbi Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1
    K S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105, USA
    Eur J Clin Microbiol Infect Dis 23:106-10. 2004
  5. ncbi Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy
    J Stambas
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    Vaccine 23:2454-64. 2005
  6. ncbi Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing
    S Surman
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    Proc Natl Acad Sci U S A 98:4587-92. 2001
  7. ncbi Structural features of HIV envelope defined by antibody escape mutant analysis
    K S Slobod
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 17:1205-9. 2001
  8. ncbi Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype
    S A Brown
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    AIDS Res Hum Retroviruses 22:188-94. 2006
  9. ncbi Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients
    K S Slobod
    Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA
    Bone Marrow Transplant 28:573-80. 2001
  10. ncbi Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein
    X Zhan
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA
    J Virol 77:4231-6. 2003

Research Grants

Collaborators

Detail Information

Publications29

  1. ncbi Molecular evidence of ocular Epstein-Barr virus infection
    K S Slobod
    Departments of Infectious Diseases, St Jude Children s Research Hospital, and Department of Pediatrics, University of Tennessee, Memphis, Tennessee, TN, USA
    Clin Infect Dis 31:184-8. 2000
    ..Recognition of EBV-induced ocular disease as an initial presentation of clinical EBV infection is important to the practitioner because of the ubiquitous nature of this herpesvirus...
  2. ncbi HIV vaccines: brief review and discussion of future directions
    Karen S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, MS 320 332 N Lauderdale, Memphis, TN 38105, USA
    Expert Rev Vaccines 4:305-13. 2005
    ..This article reviews data relevant to the development of cocktail vaccines which have been designed to elicit a wide range of envelope glycoprotein-specific B- and T-cell responses...
  3. ncbi Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults
    Karen S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Vaccine 22:3182-6. 2004
    ..Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children...
  4. ncbi Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1
    K S Slobod
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105, USA
    Eur J Clin Microbiol Infect Dis 23:106-10. 2004
    ..These findings have global implications because they support the consideration of recombinant vaccinia virus as a valuable HIV vaccine vector system...
  5. ncbi Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy
    J Stambas
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    Vaccine 23:2454-64. 2005
    ..Results highlight the D-V-P vaccination strategy as a promising approach for attaining durable, multi-isotype B-cell and T-cell activities toward HIV...
  6. ncbi Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing
    S Surman
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    Proc Natl Acad Sci U S A 98:4587-92. 2001
    ..A likely explanation is that the physical location of the peptide within the native protein leads to differential antigen processing and consequent epitope selection...
  7. ncbi Structural features of HIV envelope defined by antibody escape mutant analysis
    K S Slobod
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 17:1205-9. 2001
    ..This envelope configuration may provide an effective immune defense mechanism for HIV, as the highly variable residues of the V3 loop may shield conserved amino acids pertinent to viral infection...
  8. ncbi Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype
    S A Brown
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    AIDS Res Hum Retroviruses 22:188-94. 2006
    ..Results highlight the difficulty of predicting immune responses based on subtype alone and encourage considerations of antigenic disparity in addition to subtype disparity during HIV-1 vaccine design...
  9. ncbi Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients
    K S Slobod
    Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA
    Bone Marrow Transplant 28:573-80. 2001
    ....
  10. ncbi Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein
    X Zhan
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA
    J Virol 77:4231-6. 2003
    ..The results encourage the inclusion of more than one envelope in future vaccines to enhance the potential diversity and respective surveillance capacities of responding T-helper cell populations...
  11. ncbi T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients
    K S Slobod
    Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    Immunol Res 24:289-301. 2001
    ..The support of patients with T cell immunotherapies may ultimately revolutionize BMT, elevating the procedure from a salvage to a front-line treatment strategy for otherwise fatal disorders...
  12. ncbi Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer
    J L Shenep
    Department of Infectious Diseases, St Jude Children s Research Hospital, University of Tennessee Health Sciences Center, Memphis, TN 38105, USA
    Clin Infect Dis 32:36-43. 2001
    ..0). Results support the safety of oral cefixime therapy for low-risk febrile neutropenic children, a therapeutic approach that would facilitate earlier outpatient management and decrease the costs of treatment...
  13. ncbi A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein
    Scott A Brown
    Department of Immunology, Memphis, TN 38105, USA
    J Virol 81:12535-42. 2007
    ....
  14. ncbi HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA
    Front Biosci 13:609-20. 2008
    ..The SJCRH multi-vectored, multi-envelope vaccine has now been shown to elicit HIV-1-specific B- and T-cell functions with a diversity and durability that may be required to prevent HIV-1 infections in humans...
  15. ncbi HIV-1 envelope T cell epitope "hotspots " among mice and humans and among CD4+ and CD8+ T cell subpopulations
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 23:471-6. 2007
    ..These results emphasized the important influence that envelope peptide position may have on antigen processing, and the consequent impact such processing may have on HIV-1-specific CD4(+) and CD8(+) T-cell activities...
  16. ncbi Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, 332N Lauderdale, Memphis, TN 38105, United States
    Vaccine 25:8782-93. 2007
    ..Together, experimental results encourage promotion of this recombinant SV construct as a vaccine candidate for the prevention of RSV in humans...
  17. ncbi First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    AIDS 22:149-51. 2008
    ..Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant...
  18. ncbi Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV
    Xiaoyan Zhan
    Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA
    Vaccine 23:5306-20. 2005
    ..The present report is the first to describe pathogenic SHIV disease control mediated by a heterologous HIV-1 vaccine, devoid of 89.6 or SIV derivatives...
  19. ncbi Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus
    Toru Takimoto
    Department of Microbiology and Immunology, University of Rochester, Rochester, New York, USA
    Viral Immunol 18:255-66. 2005
    ..Sendai virus may prove an enormously valuable vaccine platform, permitting the delivery of recombinants targeting important pediatric respiratory pathogens, RSV chief among them...
  20. ncbi Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections
    Xiaoyan Zhan
    Department of Infectious Diseases, St Jude Children s Research Hospital, Memphis, TN 38105, United States
    Vaccine 26:3480-8. 2008
    ..Results encourage the continued development of the candidate recombinant SeV vaccines to combat serious respiratory infections of children...
  21. ncbi Application of the polyvalent approach to HIV-1 vaccine development
    Julia L Hurwitz
    Department of Immunology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Curr Drug Targets Infect Disord 5:143-56. 2005
    ..Information presented in this review highlights the potential and importance of the polyvalent vaccine approach for the future development of an effective HIV-1 vaccine...
  22. ncbi CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?
    Scott A Brown
    Deparment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    Curr Drug Targets Infect Disord 5:113-9. 2005
    ..Since CTL contribute to the success of vaccines in other model systems, an understanding of the strengths and possible limitations of these cells may be critical to future successes in the HIV-1 vaccine field...
  23. ncbi HIV vaccine rationale, design and testing
    Karen S Slobod
    Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105, USA
    Curr HIV Res 3:107-12. 2005
    ..Here, data relevant to the development of cocktail vaccines, designed to harness diverse, envelope-specific B-cell and T-cell responses, are reviewed...
  24. ncbi T cell epitope "hotspots" on the HIV Type 1 gp120 envelope protein overlap with tryptic fragments displayed by mass spectrometry
    Scott A Brown
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 21:165-70. 2005
    ..Results are consistent with the suggestion that gp120 peptide location influences antigen processing, which, in turn, influences the specificity of immunodominant T cells...
  25. ncbi A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?
    Timothy D Lockey
    Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA
    AIDS Res Hum Retroviruses 18:1141-4. 2002
    ..The remaining positions may be empty, or may be associated with a second, perhaps unrelated, peptide moiety...
  26. ncbi Minor components of a multi-envelope HIV vaccine are recognized by type-specific T-helper cells
    Xiaoyan Zhan
    Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, TN 38105, USA
    Vaccine 22:1206-13. 2004
    ..Our results illustrate the flexibility and durability of immune responses toward individual components of mixed envelope vaccines and encourage the continued development of vaccine cocktails for the control of HIV...
  27. ncbi Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity
    Scott A Brown
    Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
    J Immunol 171:4140-8. 2003
    ..To explain the clustering of Th cell epitopes, we propose that localization of peptide on exposed envelope surfaces facilitates proteolytic activity and preferential peptide shuttling through the Ag processing pathway...
  28. ncbi Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV
    Toru Takimoto
    St. Jude Children's Research Hospital, 332 N. Lauderdale St, Memphis, TN 38105, USA
    J Virol 78:6043-7. 2004
    ..RSV G-recombinant SV is thus a promising live virus vaccine candidate for RSV...
  29. ncbi The HIV pandemic: a forgotten crisis?
    Maxwell Madzikanga
    HIV/AIDS Programme, Africa University, Old Mutare, Zimbabwe
    Curr Drug Targets Infect Disord 5:85-6. 2005
    ..The devastation caused by HIV and AIDS has touched virtually every world region. One concern is that the unrelenting nature of the HIV pandemic fosters a disposition, not of fear and determination, but of tolerance and complacency...

Research Grants1

  1. Recombinant Sendai Virus as a Novel HIV Vaccine Vector
    KAREN SLOBOD; Fiscal Year: 2004
    ..Studies described in this application may ultimately identify rSV as an effective intranasal vaccine vehicle useful in the prevention of HIV. ..